New antibody therapy aims to stop chronic kidney transplant rejection

NCT ID NCT07689578

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests a bispecific T-cell engager (BiTE) antibody in kidney transplant recipients who have chronic active antibody-mediated rejection (cAMR). The BiTE targets BCMA and CD3 to deplete harmful B cells and plasma cells that produce donor-specific antibodies. Researchers will assess safety and whether the treatment can reduce antibody levels, improve kidney biopsy findings, and stabilize kidney function. The study enrolls 50 adults with biopsy-confirmed cAMR and stable kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA x CD3 Bispecific Antibody (BiTE)
What this could lead to: If successful, this could offer a new treatment option for kidney transplant patients with chronic rejection, potentially preserving kidney function and reducing the need for more aggressive therapies.
What could go wrong: This is a small, single-arm Phase 4 trial with no control group, so results may be preliminary. The BiTE therapy carries risks of immune-related side effects and infections, and its long-term safety in transplant recipients is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates